Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

Blood

Volumn 122, Issue 20, 2013, Pages 3482-3491

  Golay, Josée ^a   Da Roit, Fabio ^a   Bologna, Luca ^a   Ferrara, Claudia ^b   Leusen, Jeanette H ^c   Rambaldi, Alessandro ^a   Klein, Christian ^b   Introna, Martino ^a  

^a Hospital Papa Giovanni XXIII   (Italy)

^b Roche Glycart   (Switzerland)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD16B ANTIGEN; CD20 ANTIBODY; FC RECEPTOR IIA; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 6; INTERLEUKIN 8; L SELECTIN; OBINUTUZUMAB; REACTIVE OXYGEN METABOLITE; RITUXIMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CD11B ANTIGEN; CD20 ANTIGEN; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; FUCOSE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HIRUDIN DERIVATIVE; IL6 PROTEIN, HUMAN; ISOPROTEIN; ITGAM PROTEIN, HUMAN; LEPIRUDIN; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOKINE RELEASE; FOLLOW UP; HUMAN; LEUKOCYTE ACTIVATION; MODULATION; PHAGOCYTOSIS; PRIORITY JOURNAL; WILD TYPE; BIOSYNTHESIS; BLOOD; CHEMISTRY; DRUG EFFECTS; GENETICS; GLYCOSYLATION; IMMUNOLOGY; PROTEIN ENGINEERING; SECRETION (PROCESS); SURFACE PLASMON RESONANCE; UPREGULATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY AFFINITY; ANTIGENS, CD11B; ANTIGENS, CD20; FUCOSE; GLYCOSYLATION; GPI-LINKED PROTEINS; HIRUDINS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; L-SELECTIN; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEUTROPHIL ACTIVATION; PHAGOCYTOSIS; PROTEIN ENGINEERING; PROTEIN ISOFORMS; RECEPTORS, IGG; RECOMBINANT PROTEINS; SURFACE PLASMON RESONANCE; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84892422452     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-504043     Document Type: Article

References (75)

1. Martin P, Furman RR, Coleman M, Leonard JP. Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13 (18 Pt 2):5636s-5642s.
2. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011; 377(9759):42-51.
3. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104(9):2635-2642.
4. Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47(2):115-123.
5. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103(7):2738-2743.
6. Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol. 2010;47(2):107-114.
7. Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol. 2011;24(2): 203-216.
8. Robak T. Rituximab for chronic lymphocytic leukemia. Expert Opin Biol Ther. 2012;12(4): 503-515.
9. Umaña P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibodydependent cellular cytotoxic activity. Nat Biotechnol. 1999;17(2):176-180.
10. Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cellmediated B-cell cytotoxicity. Blood. 2010;115(22): 4393-4402.
11. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012; 30(8):837-842.
12. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8(3):226-234.
13. Gerdes CA, Nicolini VG, Herter S, et al. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res. 2013;19(5): 1126-1138.
14. Ferrara C, Stuart F, Sondermann P, Brünker P, Umaña P. The carbohydrate at Fcgamma RIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem. 2006;281(8):5032-5036.
15. Ferrara C, Grau S, Jäger C, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fcgamma RIII and antibodies lacking core fucose. Proc Natl Acad Sci USA. 2011;108(31): 12669-12674.
16. Radford J, Davies A, Cartron G, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood. 2013;122(7): 1137-1143.
17. Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23): 2912-2919.
18. Salles GA, Morschhauser F, Solal-Céligny P, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23):2920-2926.
19. Bologna L, Gotti E, Manganini M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol. 2011;186(6):3762-3769.
20. Kern DJ, James BR, Blackwell S, Gassner C, Klein C, Weiner GJ. GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. Leuk Lymphoma. 2013; 54(11):2500-2505.
21. Alduaij W, Ivanov A, Honeychurch J, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011;117(17):4519-4529.
22. Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. Blood. 2008;112(4): 935-945.
23. Borregaard N. Neutrophils, from marrow to microbes. Immunity. 2010;33(5):657-670.
24. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34-47.
25. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood. 2012;119(24):5640-5649.
26. Rivas-Fuentes S, García-García E, Nieto-Castañeda G, Rosales C. Fcgamma receptors exhibit different phagocytosis potential in human neutrophils. Cell Immunol. 2010;263(1):114-121.
27. Chen K, Nishi H, Travers R, et al. Endocytosis of soluble immune complexes leads to their clearance by FcγRIIIB but induces neutrophil extracellular traps via FcγRIIA in vivo. Blood. 2012;120(22):4421-4431.
28. Nagarajan S, Venkiteswaran K, Anderson M, Sayed U, Zhu C, Selvaraj P. Cell-specific, activation-dependent regulation of neutrophil CD32A ligand-binding function. Blood. 2000; 95(3):1069-1077.
29. Tsuboi N, Asano K, Lauterbach M, Mayadas TN. Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibodymediated inflammatory diseases. Immunity. 2008; 28(6):833-846.
30. van Egmond M, Bakema JE. Neutrophils as effector cells for antibody-based immunotherapy of cancer. Semin Cancer Biol. 2013;23(3): 190-199.
31. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res. 2003;9(16 Pt 1): 5866-5873.
32. Cittera E, Leidi M, Buracchi C, et al. The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab. J Immunol. 2007;178(10):6616-6623.
33. Jönsson F, Mancardi DA, Albanesi M, Bruhns P. Neutrophils in local and systemic antibodydependent inflammatory and anaphylactic reactions. J Leukoc Biol. 2013;94(4):643-656.
34. Minard-Colin V, Xiu Y, Poe JC, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood. 2008;112(4):1205-1213.
35. Biburger M, Aschermann S, Schwab I, et al. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity. 2011;35(6):932-944.
36. van der Poel CE, Karssemeijer RA, Boross P, et al. Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG. Blood. 2010; 116(24):5327-5333.
37. Bologna L, Gotti E, Da Roit F, et al. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol. 2013;190(1):231-239.
38. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95(12):3900-3908.
39. Cartron G, Ohresser M, Salles G, Solal-Céligny P, Colombat P, Watier H. Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3BNA1/NA2 polymorphism does not influence response and survival after rituximab treatment. Ann Oncol. 2008;19(8):1485-1487.
40. Golay J, Manganini M, Facchinetti V, et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica. 2003; 88(9):1002-1012.
41. Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16): 3716-3725.
42. Salmon JE, Edberg JC, Brogle NL, Kimberly RP. Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. J Clin Invest. 1992; 89(4):1274-1281.
43. Wang SY, Racila E, Taylor RP, Weiner GJ. NKcell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood. 2008;111(3):1456-1463.
44. Golay J, Bologna L, André PA, et al. Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death. Blood. 2010;116(17):3372-3373, author reply 3373-3374.
45. Ferrara C, Brünker P, Suter T, Moser S, Püntener U, Umaña P. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alphamannosidase II. Biotechnol Bioeng. 2006;93(5): 851-861.
46. Zeck A, Pohlentz G, Schlothauer T, Peter-Katalinić J, Regula JT. Cell type-specific and site directed N-glycosylation pattern of FcγRIIIa. J Proteome Res. 2011;10(7):3031-3039.
47. Ramsland PA, Farrugia W, Bradford TM, et al. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J Immunol. 2011;187(6): 3208-3217.
48. Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibodydependent cellular toxicity. J Biol Chem. 2002; 277(30):26733-26740.
49. Salmon JE, Edberg JC, Kimberly RP. Fc gamma receptor III on human neutrophils. Allelic variants have functionally distinct capacities. J Clin Invest. 1990;85(4):1287-1295.
50. Shibata-Koyama M, Iida S, Misaka H, et al. Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp Hematol. 2009;37(3):309-321.
51. Bredius RG, Fijen CA, De Haas M, et al. Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. Immunology. 1994;83(4):624-630.
52. Willcocks LC, Lyons PA, Clatworthy MR, et al. Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. J Exp Med. 2008;205(7):1573-1582.
53. van Mirre E, Teeling JL, van der Meer JW, Bleeker WK, Hack CE. Monomeric IgG in intravenous Ig preparations is a functional antagonist of FcgammaRII and FcgammaRIIIb. J Immunol. 2004;173(1):332-339.
54. Kusunoki T, Tsuruta S, Higashi H, et al. Involvement of CD11b/CD18 in enhanced neutrophil adhesion by Fc gamma receptor stimulation. J Leukoc Biol. 1994;55(6):735-742.
55. Zerria K, Jerbi E, Hammami S, et al. Recombinant integrin CD11b A-domain blocks polymorphonuclear cells recruitment and protects against skeletal muscle inflammatory injury in the rat. Immunology. 2006;119(4): 431-440.
56. Li Y, Brazzell J, Herrera A, Walcheck B. ADAM17 deficiency by mature neutrophils has differential effects on L-selectin shedding. Blood. 2006; 108(7):2275-2279.
57. Tang J, Zarbock A, Gomez I, et al. Adam17-dependent shedding limits early neutrophil influx but does not alter early monocyte recruitment to inflammatory sites. Blood. 2011;118(3):786-794.
58. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94(7):2217-2224.
59. Sehn LH, Assouline SE, Stewart DA, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood. 2012;119(22):5118-5125.
60. Salles G, Morschhauser F, Thieblemont C, et al. Efficacy and safety of obinutuzumab (GA101) monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma: results from a phase I/II study (BO20999) [abstract]. Blood. 2011;118(21): 268a.
61. Laprevotte E, Ysebaert L, Klein C, et al. Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia. Leuk Res. 2013; 37(4):440-446.
62. van der Kolk LE, de Haas M, Grillo-López AJ, Baars JW, van Oers MH. Analysis of CD20-dependent cellular cytotoxicity by G-CSFstimulated neutrophils. Leukemia. 2002;16(4): 693-699.
63. Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, et al. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood. 2008;112(6):2390-2399.
64. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol. 2010;184(1):512-520.
65. Hundt M, Schmidt RE. The glycosylphosphatidylinositol-linked Fc gamma receptor III represents the dominant receptor structure for immune complex activation of neutrophils. Eur J Immunol. 1992;22(3):811-816.
66. Huizinga TW, Dolman KM, van der Linden NJ, et al. Phosphatidylinositol-linked FcRIII mediates exocytosis of neutrophil granule proteins, but does not mediate initiation of the respiratory burst. J Immunol. 1990;144(4):1432-1437.
67. Kimberly RP, Ahlstrom JW, Click ME, Edberg JC. The glycosyl phosphatidylinositol-linked Fc gamma RIIIPMN mediates transmembrane signaling events distinct from Fc gamma RII. J Exp Med. 1990;171(4):1239-1255.
68. Edberg JC, Kimberly RP. Modulation of Fc gamma and complement receptor function by the glycosyl-phosphatidylinositol-anchored form of Fc gamma RIII. J Immunol. 1994;152(12): 5826-5835.
69. Kocher M, Siegel ME, Edberg JC, Kimberly RP. Cross-linking of Fc gamma receptor IIa and Fc gamma receptor IIIb induces different proadhesive phenotypes on human neutrophils. J Immunol. 1997;159(8):3940-3948.
70. Ebel C, Schmidt RE, Hundt M. Signal transduction via both human low-affinity IgG Fc receptors, Fc gamma RIIa and Fc gamma RIIIb, depends on the activity of different families of intracellular kinases. Immunobiology. 2001;203(4):616-628.
71. Soehnlein O, Weber C, Lindbom L. Neutrophil granule proteins tune monocytic cell function. Trends Immunol. 2009;30(11):538-546.
72. Nakagawa T, Natsume A, Satoh M, Niwa R. Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcgammaRIIIb on neutrophils. Leuk Res. 2010;34(5):666-671.
73. Salles G, Morschhauser F, Lamy T, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012;119(22):5126-5132.
74. Maloney DG, Grillo-López AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15(10):3266-3274.
75. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92(6):1927-1932.